Skip to content

BeiGene

US · ONC #538 by market cap Listed 2016
390.94 -8.76 -2.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 7.67 Expensive vs history 68th percentile
5-year average 6.32 · #449 of 511 in Biotechnology
P/E ratio 49.74 Expensive vs history 78th percentile
5-year average 28.27 · forward 40.13 · #63 of 74 in Biotechnology
P/S ratio 6.76 Cheap vs history 24th percentile
5-year average 11.51 · forward 5.93 · #154 of 392 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
BeiGene (ONC) 44.66B 49.74 7.67 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
Revolution Medicines (RVMD) 34.87B -17.66 14.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value412.74 Economic moatNarrow UncertaintyMedium

Trading 5.6% below Morningstar's fair value estimate.

Fair value

BeOne Medicines Ltd earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 3% discount to our quantitative fair value estimate of $412.74 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The firm's solid growth increases our quantitative valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 40.9% falls in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.

Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 10.8%, a core component of profitability, sits in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

BeiGene discussion 0 comments

Add a comment